Charles River Laboratories International, Inc. (NYSE:CRL) formally opened its 60,000 square foot preclinical facility in Shanghai. The international CRO and Shanghai BioExplorer formed a JV called Charles River Preclinical Services Greater China, which owns and runs the facility, with Charles River being the majority partner.
Charles River positioned the new venture as its means of providing China-based preclinical CRO services to biopharmas who are already Charles River clients. However, in earlier comments, management has said that the new venture would also seek business from domestic biopharmas.
The new facility is expected to provide Good Laboratory Practice (GLP) services in the first quarter of 2009. Plus, it will be compliant with prominent regulatory agencies around the world, including the SFDA, FDA and OECD.
Dr. Kewin Jin will serve as General Manager of Charles River Shanghai. Jin, one of the quintessential sea turtles, is a co-founder of Shanghai BioExplorer, which was established in 2002. He was trained in medicine at the Shanghai Second Medical University, received his PhD in molecular biology at Rockefeller University and studied finance at Columbia University. He has worked as an international marketing, business development, and operations executive at Wyeth (WYE) and American Home Products.